TP53 and cancer: In addition, the shared p53-Y220C neoantigen expressed by cancer cells with the amino acid sequence VVPCEPPEV, which may potentially be used to develop such immunotherapeutics, was found to have a low stability and a low affinity of binding to HLA-A0201 molecules; the altered neoantigen, in which VVPCEPPEV was substituted by VLPCEPPEV, was shown to increase affinity and stability and improve immunogenicity[83].